Research Interest: Regenerative medicine, Stem cells (transcription factors, Culture, Genomics, Clinical applications osteoarticular, Hematology, sepsis, Diabetes artheriopathy.

Biography: Young and passionate graduate in molecular and cellular biology, researcher in the field of pharmacology and oncology, with great interest in the mechanisms of angiogenesis and development of the tumor microenvironment, pharmacological resistance.

Research Interest: Molecular and cellular biology, angiogenesis, tumor angiogenesis and microenvironment, oncology pharmacology, preclinical research, natural substances and nutraceuticals

Biography: Prof. Joan Lluís Vives Corrons is Professor Emeritus at the University of Barcelona and an honorary researcher at the Josep Carreras Institute for Leukaemia Research (IJC). He has an extensive background in diagnosing rare anemias and studying the molecular bases of red blood cell (RBC) enzymopathies, membranopathies, and hemoglobinopathies.

Over more than 30 years, he served as head of the Haematology Laboratory Department (1976-1997) and head of the Red Blood Cell Pathology Unit (1998-2016). His research has focused on the physiopathology of anemia, particularly the molecular and genetic mechanisms of congenital anemias related to RBCs and erythropoietic defects. He has been the principal investigator (PI) for over 35 research projects, primarily on erythroenzymopathies like glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PK) deficiencies, hemoglobinopathies such as sickle-cell disease (SCD) and thalassemia, and hereditary hemolytic anemias (HHA) due to RBC membranopathies.

In 2002, Prof. Vives Corrons became the coordinator of the European Network for Rare and Congenital Anaemias (ENERCA), co-financed by the European Commission (EC) under its Public Health System (SANCO-Public Health). ENERCA aimed to establish a pan-European network for the diagnosis, registry, and treatment of rare anemias (RA) in Europe. Currently, he serves as chairman of the Scientific Board of the Rare Anemias International Network (RAIN), supported by the Thalassemia International Federation (TIF).

hemoglobinopathies such as sickle-cell disease (SCD) and thalassemia, and hereditary  hemolytic anemias (HHA) due to RBC membranopathies

Medical education in Bern and Geneva, MD 1978. PhD 1984 and FMH in pathology 1988 in Basel.

Positions held: 1974 Immunology University of Bern, 1979 Pharmacology, Sandoz Pharma Basel, 1991 University of Zurich, Pharmacology-Toxicology, Immunology University Cape Town, RSA. Since 2001 Director of research, CNRS Immunology, Orleans, France with active research, and advisor of several pharmaceutical companies. Founder of IBR Inc, Artimmune SAS and Phenotec AG.

Research Interests: Mechanisms of inflammation, especially respiratory inflammation, fibrosis, emphysema and COPD, but also in skin, hepatic, intestinal, renal and CNS inflammation. Cell death, innate immune danger sensing and cGAS/STING, ROS and Inflammasome activation in models of human inflammatory diseases and tumor development, role of microbiome, metabolome, neuroinflammation/degeneration and ageing.

Role of TNF and IL-1 members, in cell death and IL-33 and T2 / T17 polarization and differentiation.

PB drug candidate Stable butyrate to treat chronic lung inflammatory disease

Research Interest: Hematology and Oncology

Research Interest: Pediatric Hematology & Oncology